Advagene Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Advagene Biopharma has a total shareholder equity of NT$140.0M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$147.9M and NT$8.0M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$125.19m |
| Equity | NT$139.96m |
| Total liabilities | NT$7.97m |
| Total assets | NT$147.93m |
Financial Position Analysis
Short Term Liabilities: 6709's short term assets (NT$146.4M) exceed its short term liabilities (NT$8.0M).
Long Term Liabilities: 6709 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6709 is debt free.
Reducing Debt: 6709 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6709 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6709 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 9.9% each year.